Memorial Sloan Kettering Cancer Center Giving

Donate now at http://mskcc.convio.net/goto/low-grade-serous

The gynecologic medical oncology group at Memorial Sloan Kettering Cancer Center (MSKCC) is dedicated to researching and developing novel treatment strategies for rare ovarian cancers.

It is their mission to increase the number of women with low grade serous ovarian cancer who are cured through research, clinical trials and tailored care for their patients.

Dr Grisham Cancer Researcher

Dr. Rachel Grisham is the Section Head of Ovarian Cancer at MSKCC and her research specifically focuses on the development of new treatments for low grade serous ovarian cancer. She and her colleagues have previously helped to better define the molecular profile of low grade serous ovarian cancer and characterize prognostic molecular and radiographic markers for this disease. She has led several clinical trials examining novel hormonally and molecularly targeted therapies for treatment of this disease, including an ongoing phase II study of the antiandrogen, onapristone, for treatment of women with recurrent disease.

Support MSKCC’s research

100% of your donations through this page go directly to low-grade serous carcinoma research. Donations over $10 are tax deductible.
Donate now at http://mskcc.convio.net/goto/low-grade-serous

Low-grade serous research publications that MSKCC researchers have contributed to:

BRAF V600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary.
Turashvili G, Grisham RN, Chiang S, DeLair DF, Park KJ, Soslow RA, Murali R. Histopathology. 2018 Sep;73(3):438-443. doi: 10.1111/his.13651. Epub 2018 Jun 22. PMID:29770477

CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas. Nougaret S, Lakhman Y, Molinari N, Feier D, Scelzo C, Vargas HA, Sosa RE, Hricak H, Soslow RA, Grisham RN, Sala E. AJR Am J Roentgenol. 2018 Apr;210(4):918-926. doi: 10.2214/AJR.17.18254. Epub 2018 Feb 28.PMID: 29489407

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs DR, Aghajanian CA, Solit DB, Iyer G. J Clin Oncol. 2015 Dec 1;33(34):4099-105. doi: 10.1200/JCO.2015.62.4726. Epub 2015 Aug 31. PMID: 26324360

The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer. Monk BJ, Randall LM, Grisham RN. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e141-e151. doi: 10.1200/EDBK_239007. Epub 2019 May 17. PMID: 31099631

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders. Grisham RN, Moore KN, Gordon MS, Harb W, Cody G, Halpenny DF, Makker V, Aghajanian CA. Clin Cancer Res. 2018 Nov 15;24(22):5525-5533. doi: 10.1158/1078-0432.CCR-18-0494. Epub 2018 May 29. PMID: 29844129

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C. Int J Gynecol Cancer. 2014 Jul;24(6):1010-4. doi: 10.1097/IGC.0000000000000190. PMID: 24978709

Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions. Grisham RN, Iyer G. Curr Treat Options Oncol. 2018 Sep 18;19(11):54. doi: 10.1007/s11864-018-0571-8. Review. PMID: 30225651

Share this: